February 25, 2021
Business News

Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases


PARIS & LONDON–()–Servier, a global and independent pharmaceutical Group, and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.

As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialization of any products resulting from the collaboration. Under the terms of the agreement, MiNA Therapeutics will receive an…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Gabelli Utility Trust Continues Monthly Distributions, Declares Distributions of $0.05 Per Share
AEye and CF Finance Acquisition Corp. III Announce Continental AG’s Participation in $225 Million Pipe Offering
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Apache Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm